U.S. markets open in 7 hours 42 minutes
  • S&P Futures

    4,198.00
    +3.75 (+0.09%)
     
  • Dow Futures

    34,460.00
    +18.00 (+0.05%)
     
  • Nasdaq Futures

    13,632.25
    +34.50 (+0.25%)
     
  • Russell 2000 Futures

    2,239.90
    0.00 (0.00%)
     
  • Crude Oil

    65.20
    +0.49 (+0.76%)
     
  • Gold

    1,819.10
    +3.40 (+0.19%)
     
  • Silver

    27.44
    -0.03 (-0.12%)
     
  • EUR/USD

    1.2067
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.5610
    0.0000 (0.00%)
     
  • Vix

    18.39
    -0.76 (-3.97%)
     
  • GBP/USD

    1.3911
    +0.0018 (+0.13%)
     
  • USD/JPY

    109.0830
    -0.0020 (-0.00%)
     
  • BTC-USD

    55,951.54
    -1,111.75 (-1.95%)
     
  • CMC Crypto 200

    1,452.01
    -19.40 (-1.32%)
     
  • FTSE 100

    7,076.17
    +36.87 (+0.52%)
     
  • Nikkei 225

    29,379.77
    +48.40 (+0.17%)
     

Biogen, Bio-Thera Ink Licensing Agreement For Development Of Actemra-Based Biosimilar For Rheumatoid Arthritis

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Biogen Inc (NASDAQ: BIIB) and Bio-Thera Solutions Ltd have entered into a commercialization and license agreement to develop, manufacture, and commercialize BAT1806, a proposed biosimilar referencing Genentech's Actemra (tocilizumab).

  • The anti-interleukin-6 (IL-6) receptor monoclonal antibody is currently in a Phase 3 study.

  • Actemra's primary indication is for moderate to severe rheumatoid arthritis in adults and juvenile idiopathic polyarthritis, systemic juvenile idiopathic arthritis, giant cell arteritis, and cytokine release syndrome.

  • Biogen will gain exclusive regulatory, manufacturing, and commercial rights to BAT1806 in all countries, excluding China (including Hong Kong, Macau, and Taiwan).

  • Under the terms of the agreement, Biogen will make an upfront payment of $30 million to Bio-Thera Solutions, contingent upon Bio-Thera Solutions' Phase 3 for BAT1806 achieving satisfactory results.

  • Bio-Thera Solutions is also eligible to receive potential milestone payments, as well as tiered royalties.

  • The transaction is expected to close in the second quarter of 2021.

  • Price Action: BIIB shares are down 0.05% at $267.88 in the market trading session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.